NCT07128381View on ClinicalTrials.gov

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

July 31, 2031

Study Completion Date

July 31, 2033

Conditions
Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)
Interventions
DRUG

Axatilimab (SNDX-6352)

Taken orally

DRUG

Ruxolitinib

Taken orally

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Incyte, Inc
All Listed Sponsors
collaborator

Incyte, Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT07128381 - Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Biotech Hunter | Biotech Hunter